All In Biotech

Investigational drug · Phase 2

Remzistotug

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neoplasms, Head and Neck.

Phase 2

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "Remzistotug"

First trial start

2023

Nov 14, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Remzistotug", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neoplasms, Head and Neck

Approved drugs for the same conditions: Head and neck cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Remzistotug" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Neoplasms, Head and Neck

  • BelrestotugEOS884448, GSK4428859APhase 33 trials

    GSK · Lung Cancer, Non-Small Cell, Neoplasms, Head and Neck

  • NelistotugGSK6097608Phase 22 trials

    GSK · Lung Cancer, Non-Small Cell, Neoplasms, Head and Neck

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.